biotech · Chronic Hepatitis D Virus (HDV) Infection · Chronic Hepatitis B · VIR
Vir Biotechnology
Vir Biotechnology is a biotech organization headquartered in San Francisco, USA. It trades on NYSE under ticker VIR. Primary therapeutic focus areas include Chronic Hepatitis D Virus (HDV) Infection, Chronic Hepatitis B,
Company details
- Status
- Public
- HQ
- 1800 Owens St, Suite 900, San Francisco, California 94158, US
- Founded
- 2016
- Employees
- 479
- Programs
- 34
- Drugs
- 17
- Patents
- 6
Quick answer
Vir Biotechnology is a biotech organization headquartered in San Francisco, USA. It trades on NYSE under ticker VIR. Primary therapeutic focus areas include Chronic Hepatitis D Virus (HDV) Infection, Chronic Hepatitis B, Covid19, COVID-19, Hepatitis B, Chronic. NovaPharmaNews links 34 clinical program(s), 0 drug profile(s), and 6 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (17), phase 1 (10), phase 3 (7).
Company snapshot
At Vir Biotechnology, Inc., we leverage the immense potential of the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. We focus on the therapeutic areas in which we believe we can most benefit patients. Our foundational efforts in chronic hepatitis delta are complemented by strategic programs in oncology. Every day, we work with th
- 34 active pipeline program(s) linked via ClinicalTrials.gov.
- 6 US patent(s) indexed to this assignee profile.
- 34 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for Vir Biotechnology. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
Gilead Secures First Hepatitis D Drug Approval, Sparking Bay Area Competition
- deal
Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM
Recent coverage
Vir Biotechnology Stock: Board Reshuffle and Governance Votes Post-AGM
Vir Biotechnology is undergoing significant leadership changes post-AGM, with a board reshuffle and key governance votes set to influence its strategic direction. Investors and pharmaceutical BD teams should monitor these developments for potential shifts in clinical trial focus and market positioning.
Gilead Secures First Hepatitis D Drug Approval, Sparking Bay Area Competition
Gilead Sciences has achieved a significant milestone with the FDA approval of bulevirtide, the first drug to treat chronic hepatitis D. This landmark decision intensifies the competitive landscape as Bay Area rivals Vir Biotechnology and Mirum Pharmaceuticals advance their own therapies.
Top assets
Lead pipeline drugs
- Marketed / approved
- Marketed / approved
- Marketed / approved
- approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 3
- Phase 3
Momentum
Proprietary activity score for Vir Biotechnology.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for Vir Biotechnology.
- Clinical update
- Clinical update
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is Vir Biotechnology?
-
Is Vir Biotechnology publicly traded?
-
What drugs does Vir Biotechnology develop or market?
-
What are the latest developments for Vir Biotechnology?
-
What therapeutic areas does Vir Biotechnology focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.